Key Investor Signals
€3.5M Seed round led by HTGF and backed by IBB
The October 2024 round also included caesar., Business Angel Club Berlin, angels and family offices, funding product development and planned patient and animal studies.
Patient trial advances to early clinical readouts
An ongoing study evaluates home-based visual stimulation in mild cognitive impairment and Alzheimer’s disease, with early readouts presented at AD/PD and AAIC in 2026.
Strategic partnership with Roche subsidiary RoX Health
RoX Health has supported Nuuron from its early development through a strategic collaboration, adding a pharmaceutical digital-health partner to its clinical translation effort.
Other Positive Signals
- Nuuron published a PCT patent application for a device inducing high-frequency brain oscillations.
- An eight-patient mechanistic study found increased memory-related brain signals during visual stimulation.
Team
Fabian Queisner
CEO and Co-founder
- Former CEO of Ababax.Health, a life-science venture studio building therapies in neurology and ophthalmology.
- Former CEO of neuraltrain, which developed a neurotechnology device targeting depression and anxiety disorders.
- Led strategy and operations at Eternity.Health, a holding company spanning health investment and venture building.
Dr. Markus Müschenich
Co-founder
- Physician with pediatric clinical experience and public-health training, combining medical practice with health-system knowledge.
- Served on Sana Kliniken’s board from 2009 to 2012, including a final period as Chief Medical Officer.
- Founded Flying Health in 2012 and became Managing Partner of Eternity.Health, building a healthcare venture ecosystem.
Product
The Memory Pacemaker is an investigational medical device designed to stimulate memory-related brain activity without surgery. Software controls patterns of light delivered to the eyes, with a smart-glasses format being evaluated for use at home in Alzheimer’s disease.
Targeting memory-related activity
The stimulation aims to increase sharp-wave ripples in the hippocampus, a brain region involved in memory. The approach targets the electrical activity underlying memory formation and recall rather than delivering a chemical drug.
Spatially timed retinal stimulation
The software combines fast flickering light with spatial patterns that stimulate neighboring retinal areas at different times. This arrangement is designed to generate higher-frequency brain activity through the visual pathway.
Home-based light delivery through glasses
The current clinical approach delivers non-invasive visual stimulation through smart glasses for use at home. The glasses provide the light interface, while software determines the stimulation patterns used during treatment.
Market Overview
Alzheimer’s care combines medication, cognitive support and assistance with daily living. As memory and functional decline progress, patients need increasing support. Limited dementia-specialist capacity makes approaches that can be delivered and monitored outside specialist centers increasingly relevant.
Dementia places substantial costs on public insurers and families, giving providers and payers reasons to evaluate treatments that could sustain independence. For home-based devices, adoption depends on convincing evidence of cognitive benefit, usability and safety, alongside a viable prescription and reimbursement pathway.
Americans aged 65 and older estimated to be living with Alzheimer’s in 2026.
Projected US health and long-term care spending for dementia in 2026, excluding unpaid care.
Unpaid care provided by Americans for people with Alzheimer’s or other dementias in 2025.
Share of US primary care physicians reporting too few dementia specialists in their communities.
Comparable Outcomes
Axonics
Developed implantable nerve-stimulation systems that helped treat bladder and bowel control disorders. Boston Scientific completed the $3.7B acquisition in November 2024, expanding its urology portfolio with sacral neuromodulation devices.
Avid Radiopharmaceuticals
Developed PET imaging agents designed to detect amyloid plaques associated with Alzheimer's disease. Eli Lilly acquired Avid in 2010 for $300M upfront plus up to $500M in milestone payments tied to florbetapir.
Interested in More Startups Like Nuuron?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.